Considering the existing data, previous bioinformatics analysis, and transcriptome sequencing results, it can be inferred that SHMT2, one of the two isozyme genes of serine hydroxymethyltransferase, is more likely to be a potential driver of bladder cancer than SHMT1. This evidence concerns the gene SHMT2 and urinary bladder carcinoma.